A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

NCT00639691 · clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
48
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis